BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32917271)

  • 1. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China.
    Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P
    Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
    COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
    Tse HN; Raiteri L; Wong KY; Yee KS; Ng LY; Wai KY; Loo CK; Chan MH
    Chest; 2013 Jul; 144(1):106-118. PubMed ID: 23348146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early intervention with tiotropium in Chinese patients with GOLD stages I-II chronic obstructive pulmonary disease (Tie-COPD): study protocol for a multicentre, double-blinded, randomised, controlled trial.
    Li X; Zhou Y; Chen S; Zheng J; Zhong N; Ran P
    BMJ Open; 2014 Feb; 4(2):e003991. PubMed ID: 24549160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
    Tse HN; Tseng CZ
    Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee.
    Decramer M; Dekhuijzen PN; Troosters T; van Herwaarden C; Rutten-van Mölken M; van Schayck CP; Olivieri D; Lankhorst I; Ardia A
    Eur Respir J; 2001 Mar; 17(3):329-36. PubMed ID: 11405507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
    Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
    Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study protocol for a randomized controlled trial.
    Xie S; Yan P; Yao C; Yan X; Huo Y; Zhang J; Liu S; Feng Z; Shang H; Xie L
    Trials; 2019 Feb; 20(1):136. PubMed ID: 30777117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial.
    Kong Q; Mo S; Wang W; Tang Z; Wei Y; Du Y; Liu B; Kong L; Lv Y; Dong J
    Trials; 2020 Sep; 21(1):760. PubMed ID: 32883322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of
    Huang C; Kuo S; Lin L; Yang Y
    Ther Adv Respir Dis; 2023; 17():17534666231158563. PubMed ID: 36927162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the Chinese herbal formula San-Huang Gu-Ben Zhi-Ke treatment on stable chronic obstructive pulmonary disease: study protocol of a randomized, double-blind, placebo-controlled trial.
    Zu Y; Li D; Lei X; Zhang H
    Trials; 2019 Nov; 20(1):647. PubMed ID: 31775843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
    Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
    Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Chinese medicine on patients with acute exacerbations of COPD: study protocol for a randomized controlled trial.
    Zhang H; Li J; Yu X; Li S; Wang H; Ruan H; Si Y; Xie Y; Wang M
    Trials; 2019 Dec; 20(1):735. PubMed ID: 31842969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
    Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
    Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
    Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
    Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
    Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of N-acetylcysteine in patients with non-cystic fibrosis bronchiectasis (NINCFB): study protocol for a multicentre, double-blind, randomised, placebo-controlled trial.
    Liao Y; Wu Y; Zi K; Shen Y; Wang T; Qin J; Chen L; Chen M; Liu L; Li W; Zhou H; Xiong S; Wen F; Chen J
    BMC Pulm Med; 2022 Nov; 22(1):401. PubMed ID: 36344940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study.
    Stav D; Raz M
    Chest; 2009 Aug; 136(2):381-386. PubMed ID: 19447919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.